Ronald McCall Net Worth

The estimated Net Worth of C Elkins Ronald is at least $2.83 million dollars as of 5 September 2018. Mr. Ronald owns over 5,000 units of Artivion Inc stock worth over $1,159,393 and over the last 21 years he sold CRY stock worth over $1,474,109. In addition, he makes $195,015 as Presiding Independent Director at Artivion Inc.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Mr. McCall CRY stock SEC Form 4 insiders trading

Ronald has made over 31 trades of the Artivion Inc stock since 2007, according to the Form 4 filled with the SEC. Most recently he sold 5,000 units of CRY stock worth $172,650 on 5 September 2018.

The largest trade he's ever made was exercising 30,000 units of Artivion Inc stock on 29 May 2007 worth over $179,100. On average, Ronald trades about 2,572 units every 70 days since 2003. As of 5 September 2018 he still owns at least 64,843 units of Artivion Inc stock.

You can see the complete history of Mr. Ronald stock trades at the bottom of the page.

Ronald McCall biography

Ronald D. McCall Esq. serves as Presiding Independent Director of the Company., is an Independent Director of CryoLife, Inc., Mr. McCall has served as a director of CryoLife since January 1984. From 1985 to the present, Mr. McCall has been the owner of the law firm Ronald D. McCall, P.A., based in Tampa, Florida. Mr. McCall was admitted to the practice of law in Florida in 1961. Mr. McCall received a B.A. and a J.D. from the University of Florida.

What is the salary of Ronald McCall?

As the Presiding Independent Director of Artivion Inc, the total compensation of Ronald McCall at Artivion Inc is $195,015. There are 10 executives at Artivion Inc getting paid more, with James Mackin having the highest compensation of $6,453,540.

How old is Ronald McCall?

Ronald McCall is 83, he's been the Presiding Independent Director of Artivion Inc since 2005. There are no older and 23 younger executives at Artivion Inc.

What's Ronald McCall's mailing address?

C's mailing address filed with the SEC is C/O CRYOLIFE, INC., 1655 ROBERTS BOULEVARD, N.W., KENNESAW, GA, 30144.

Insiders trading at Artivion Inc

Over the last 21 years, insiders at Artivion Inc have traded over $18,346,910 worth of Artivion Inc stock and bought 91,700 units worth $1,086,548 . The most active insiders traders include Steven G Anderson, Thomas F Ackerman et James P Mackin. On average, Artivion Inc executives and independent directors trade stock every 26 days with the average trade being worth of $211,842. The most recent stock trade was executed by Amy Horton on 8 December 2021, trading 2,500 units of CRY stock currently worth $46,425.

What does Artivion Inc do?

Headquartered in suburban Atlanta, Georgia, CryoLife is a leader in the manufacturing, processing, and distribution of medical devices and implantable tissues used in cardiac and vascular surgical procedures focused on aortic repair. CryoLife markets and sells products in more than 100 countries worldwide.

Complete history of Mr. Ronald stock trades at Artivion Inc

Artivion Inc executives and stock owners

Artivion Inc executives and other stock owners filed with the SEC include:

• James Mackin,
  Chairman of the Board, President, Chief Executive Officer, Director
• D. Ashley Lee,
  Chief Financial Officer, Chief Operating Officer, Executive Vice President
• Jean Holloway,
  Senior Vice President, Chief Compliance Officer, General Counsel, Secretary
• Michael Simpson,
  Senior Vice President - Regulatory Affairs and Quality Assurance
• John Davis,
  Senior Vice President - Global Sales and Marketing
• James Patrick Mackin,
  Chairman, Pres & CEO
• Scott Capps,
  Vice President - Clinical Research
• David Ashley Lee CPA, CPA,
  Exec. VP, COO & CFO
• Jean F. Holloway Esq.,
  Sr. VP, Gen. Counsel, Chief Compliance Officer & Corp. Sec.
• John E. Davis,
  Sr. VP of Global Sales & Marketing
• Harvey Morgan,
  Independent Director
• Daniel Bevevino,
  Independent Director
• Ronald McCall,
  Presiding Independent Director
• Thomas Ackerman,
  Independent Director
• Jon Salveson,
  Independent Director
• James Bullock,
  Independent Director
• Jeffrey Burbank,
  Independent Director
• Marna Borgstrom,
  Independent Director
• Greg Chodaczek,
  IR Contact Officer
• Matthew Getz,
  Vice President - Human Resources
• Dennis Maier,
  Vice President - Operations
• Amy Horton,
  Chief Accounting Officer, Vice President
• Thomas Bogenschutz,
  Senior Vice President - EMEA, General Manager - Hechingen
• Dr. Marshall S. Stanton,
  Sr. VP of Clinical Research & Chief Medical Officer
• Joshua Wells,
  Sr. Director of Bus. Devel.
• Matthew A. Getz,
  VP of HR
• Amy D. Horton CPA, CPA,
  VP & Chief Accounting Officer
• Sherry M Saurini,
  VP, Quality
• C Elkins Ronald,
  Director
• James Benson,
  Director
• James M Mc Dermid,
  SVP, CHRO
• David C Gale,
  VP-Research and Development
• William Robert Matthews,
  Senior VP, Operations, Quality
• Thomas J Bogenschuetz,
  VP, EMEA & General Manager
• Bruce G. Anderson,
  VP, US Sales and Marketing
• Jeffrey W Burris,
  Vice President & Gen. Counsel
• Gerald B Seery,
  Sr. VP, Sales and Marketing
• John M Cook,
  Director
• David P. Lang,
  Sr. VP, Intl Sales & Marketing
• Steven G Anderson,
  President, CEO and Chairman
• Thomas J Lynch,
  VP - Reg. Aff./Quality Assur.
• Capital Management Oss,
  10% owner
• Philip A Theodore,
  VP, General Counsel
• Michaelstark Brian Jay Roth,
  
• Sidney B Ashmore,
  Vice President of Marketing
• Virginia C Lacy,
  Director
• Dyne Bruce J Md Van,
  Director
• Albert E Heacox,
  Sr. VP-Laboratory Operations
• Vander James C Wyk,
  VP - Product Integrity
• Kirby S Black,
  Sr. Vice President, R&D
• David Fronk,
  VP - Clinical Research
• Rochelle L. Maney,
  VP, Quality
• Franz Peter Barthold,
  VP, Research & Development
• Marshall S. Stanton,
  SVP, Clinical & MD Affair
• Anthony B. Semedo,
  Director